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ABSTRACT
The antigenicity of cells is demarcated by the peptides bound by their Human 
Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell 
specificity response is controlled. As a fraction of the expressed mutated peptides 
is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-
antigens have recently been identified through screening for predicted mutated 
peptides, using synthetic peptides or ones expressed from minigenes, combined with 
screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time 
and cost-effective method that combines whole-exome sequencing analysis with HLA 
peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 
1,019 amino acid changes identified through exome sequencing, two were confirmed 
by mass spectrometry to be presented by the cells. We then synthesized peptides and 
evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and 
found that one yielded mutant-specific T-cell response. Our results demonstrate that 
this method can be used for immune response prediction and promise to provide an 
alternative approach for identifying immunogenic neo-epitopes in cancer.
INTRODUCTION
Antigen presentation through the binding of peptides 
to cellular HLA molecules modulates T cell response 
specificity, and thus determines cell antigenicity. CD8+ 
cytotoxic T lymphocytes (CTLs) have the potential to 
recognize tumor cells via specific peptide-HLA binding, 
leading to tumor regression following immunotherapy [1]. 
One class of antigens promoting this recognition is the 
tumor-associated self-antigens. However, neo-epitopes, 
that arise as a consequence of somatic mutations in the 
tumor, are another antigen subgroup that induces anti-
tumor CTL responses [2, 3].
The main screening method currently used to 
identify neo-antigens relies on identification of tumor 
somatic mutations by whole-exome sequencing, followed 
by in silico analysis of candidate mutated peptides, to 
calculate their theoretical affinity for the patient’s HLA 
complex [4]. Synthetic peptides of the selected sequences 
are then pulsed on antigen presenting cells [2, 5], or 
loaded on tetramers [6], to evaluate their immunogenicity 
when introduced to autologous T- cells. The success of this 
method crucially depends on the accuracy of peptide-MHC 
binding prediction algorithms, which are often inadequate, 
and produce large numbers of candidate mutant peptides. 
Another method, that eliminates the need to predict 
peptide-MHC binding, is the use of tandem minigenes 
encoding each expressed cancer-specific mutation. These 
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minigenes are expressed in the patients’ autologous 
antigen presenting cells and then tested for reactivity with 
the patients’ T cells [7, 8]. Subsequent validation of both 
the abovementioned neo-antigen screening methods is 
labor-intensive and time-consuming.
The collection of HLA class I (HLA-I) bound 
peptides expressed by a particular cell, otherwise known 
as the cell’s ‘HLA peptidome’, reflects the set of proteins 
found in that cell. The HLA peptidome serves as a 
unique immunological signature that can be selectively 
recognized by CTLs, potentially leading to cell lysis. 
Recent advances in mass spectrometry make it possible 
to analyze the HLA peptidome in great detail [9]. 
Here, we report the first analysis of the mutated HLA-I 
peptidome of human melanoma tumor cells, using a 
novel strategy, that combines whole-exome sequencing 
and mass spectrometry analysis. Using this method, 
we experimentally identified mutated peptides that are 
actually processed and presented by the tumor HLA 
molecules, and proceed to assess only those empirically 
identified candidates for testing immunogenicity. 
RESULTS
Identification of melanoma neo-antigens 
To identify mutated antigens presented on human 
melanoma tumor cells, we re-sequenced the whole 
genomes of matched normal and metastatic tumor DNAs 
from a melanoma patient and identified their somatic 
mutations (Supplementary Table 1). 
In parallel to our whole exome analysis, we 
performed immunoaffinity purification of the HLA 
molecules from the same patient’s melanoma cells, 
followed by capillary chromatography and tandem 
mass spectrometric analysis of HLA peptides. The mass 
spectrometry spectra were analyzed using MaxQuant [10] 
software tool and queried against the human proteome 
dataset (Uniprot) to which we manually added the amino 
acid changes corresponding to the mutations identified by 
our whole-genome sequencing. 
Among the 4,958 peptides detected by mass 
spectrometry, we identified two patient-derived mutated 
peptides (Figure 1). The first peptide is a nonamer derived 
from the P677S alteration in Mediator of RNA polymerase 
II transcription subunit 15 (MED15) and the second 
peptide is an elevenmer derived from the S123L alteration 
in Tumor Protein D52-Like 2 (TPD52L2) protein. Peptide 
identification accuracy was validated by comparison of 
endogenous peptide spectra to synthetic peptide spectra 
(Supplementary Figure 1). Both wild-type and mutant 
transcripts corresponding to the peptides were expressed 
in the 12T tumor cell line (Supplementary Figure 2 and 
Supplementary Table 2).
Immunogenicity evaluation of the identified neo-
antigens 
To evaluate the peptides’ ability to elicit an immune 
response we pulsed synthetic MED15 and TPD52L2 
mutant peptides and their wild-type version, on Epstein 
bar virus (EBV)-transformed B cells established from the 
patients’ peripheral blood mononuclear cells (PBMCs) 
and co-cultured these cells with the autologous TILs. As 
seen in Figure 2, the mutated MED15 peptide stimulated 
interferon-γ (IFN-γ) release from the TILs, whereas the 
mutant TPD52L2 peptide did not show any response.
Figure 1: Tandem mass spectra of endogenous mutant peptides identified in 12T. a. KLFEDRVGTIK b. DANSFLQSV. 
Mutation sites are indicated with the amino acid underlined.
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Figure 3: Response of the TILs to MED15 and TPD52L2 mutant and wild-type peptides in the context of HLA-B*51. 
A. IFN-γ release measured after overnight co-culture of the TILs with T2 cells that were pulsed with 1μM of the mutated or wild-type 
peptides or with the autologous and allogenic melanoma cells. B. IFN-γ release measured after overnight co-culture of 12T TILs with T2 
cells that were pulsed with tittered concentrations of the MED15 mutated and wild-type peptides. Error bars represent standard deviation 
of triplicates.
Figure 2: Response of the TIL to candidate neo-antigens identified from its autologous tumor. IFN-γ release measured after 
overnight co-culture of the TIL with autologous EBV transformed B cells that were pulsed with 1μM of the mutated or wild-type peptides. 
Error bars represent standard deviation of triplicates.
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To determine the HLA allele to which the mutant 
MED15 peptide binds, we pulsed it on cells of the T2 
line, which is B*51 positive [11], then cultured the cells 
with the patient’s TILs. Remarkably, the IFN-γ released 
following pulsing these cells with mutant MED15 peptide 
was comparable to that measured after TILs stimulation 
by the patient’s autologous tumor cells (17,000 pg 
ml−1 compared to 18,700 pg ml−1 with the autologous 
melanoma), indicating that the peptide binds the B*51 
allele. Importantly, when cells of the T2 line were pulsed 
with the wild-type version of the MED15 peptide, a 
substantially weaker response was detected (300 pg ml−1 
in the experiment detailed in Figure 3A). 
Peptide titration assays further confirmed that the 
patient’s TILs were highly reactive with T2 cells pulsed 
with the mutated MED15 peptide, which was recognized 
at a minimum concentration of 10 nM (Figure 3B). 
Meanwhile, a response to the MED15 wild-type peptide 
was only observed when T2 cells were pulsed with peptide 
concentrations two orders of magnitude higher. Mutant 
MED15 peptide therefore appears to represent a naturally 
processed epitope recognized by the patient’s TILs (Figure 
3B). 
To further evaluate TILs reactivity with the mutant 
MED15 peptide, we preformed intracellular IFN-γ staining 
after co-culturing the TILs with the autologous melanoma 
as a reference for total reactivity or with T2 cells pulsed 
with the mutant or wild-type MED15 peptides. About 21% 
of the TILs were reactive against the melanoma cells and 
about 9% were reactive against the T2 cells pulsed with 
the mutant MED15 peptide. Therefore, we estimate that 
approximately 40% of the reactive TILs specifically react 
with the mutant peptide (Figure 4), suggesting that it is an 
immunodominant epitope.
Prediction of neo-antigens using NetMHCpan 
algorithm
We were interested to compare our method to the 
currently prevalent algorithmic prediction method. To that 
end, we used The NetMHCpan 2.8 algorithm, to predict all 
possible neo-antigens derived from 12T non-synonymous 
mutations, for all the cells’ HLA alleles and between 8-12 
amino acids in length. In total, 5,404 different peptides 
were predicted (Supplementary Table 3). 
Binding affinity predictions for wild-type and 
mutant peptides of MED15 and TPD52L2 are in 
Supplementary Table 4. The mutant and wild-type 
TPD52L2 peptides were predicted to bind the A*03 allele 
strongly and weakly, respectively and the MED15 mutant 
and wild-type peptide were predicted to weakly bind the 
B*51 allele.
Figure 4: Intracellular staining of IFN-γ after stimulation with the peptides and melanoma. Intracellular IFN-γ was stained 
after 6 hours co-culture of the TILs with T2 cells that were pulsed with 1μM of the mutated or wild-type peptides or with the autologous 
melanoma.
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DISCUSSION
This report is the first to show that a combination 
of HLA peptidomics and autologous cancer exome data 
can be used to reveal cancer-specific antigens which 
expose neo-antigen, leading to a specific T cell response in 
humans. Currently, most neo-antigen identification studies 
use algorithms, such as NetMHCpan [4], to predict which 
mutated peptide sequences can bind the patients’ HLA 
alleles. As the HLA peptide processing steps are not fully 
known, and therefore cannot be taken into consideration 
within the prediction algorithm, these predictions yield a 
large number of false positive hits, that must then all be 
screened. Several criteria are usually used to reduce the 
number of screened peptides. These include: predicted 
binding affinity, length of the predicted peptides and their 
expression levels. Applying such limitations can exclude 
peptides such as the mutated MED15 peptide which was 
predicted to weakly bind the B*51 molecule. In contrast, 
isolation of HLA peptides directly from tumor cells 
ensures that only peptides that are actually processed in 
the cells, bind the HLA and are presented on the cells’ 
surface are tested for immunogenicity. Therefore more 
concerning than the added labor entailed by the multitude 
of candidate peptides, is the fact that the currently utilized 
filtering criteria also run the risk of producing false 
negative hits, thus missing peptides that might actually 
bind the HLA, as in the case demonstrated in this work. 
The proposed method, depicted in Supplementary 
Figure 3, allows for identification of neo-antigens in 
significantly less time than currently used screening 
methods. While other methods require whole exome 
sequencing and identification of somatic mutations prior 
to wide-scale-screen with synthetic peptides, tetramers 
or construction of minigenes, mass spectrometry analysis 
of the peptides isolated from the tumor can be done in 
parallel, saving valuable time. Subsequent immunological 
assays for validation of the peptides identified by mass 
spectrometry only require synthesis of a few peptides 
compared to the hundreds of peptides that are needed for 
screening predicted sequences. Importantly, the number 
of reactive neo-antigens identified using this method is 
similar to the number of peptides identified by the other 
currently used methods (between 0-3 peptides per sample) 
[12, 13, 14, 6, 15].
As in all mass spectrometry analyses, identification 
is biased toward the most abundant peptides. Therefore, 
identifying a larger number of total HLA peptides will 
increase the chance of discovering neo-antigens. In this 
study HLA peptides were isolated from 2*108 cells, which 
is the estimated number of cells in clinically detectable 
solid human tumors [16], making this method applicable 
for neo-antigen identification directly from the isolated 
tumor, without the need to establish a tumor cell line.
Finally, using flow cytometry analysis of 
intracellular IFNγ, we demonstrated that about 40% of 
TILs reactivity against the melanoma cells is attributable 
to specific reactivity to the mutated MED15 peptide. This 
result corroborates previous observations showing that 
autologous T- cell response is driven mainly by mutated 
neo-antigens [17, 18].
Here we provide, to our knowledge, the first 
demonstration of an approach that combines two powerful 
tools, forming an alternative system for identifying 
immunogenic neo-epitopes in human cancer. This 
approach may be used clinically as a potential diagnostic 
strategy for personalized immunotherapy, not only for 
melanoma patients but for a variety of additional tumor 
types where neo-antigens play a critical role in anti-tumor 
reactivity.
MATERIALS AND METHODS
Tumor tissues 
All DNA samples used in this study were derived 
from metastases. Samples used for whole-exome capture 
were extracted from cell lines established directly from 
patient tumors as described previously [19]. We identified 
somatic mutations by comparing the tumor data to the 
matched normal tissue and identified 2,997 potential 
somatic mutations in 2,192 different genes. Of these 
alterations, 1019 caused amino acid changes consistent 
with prior data [19].
12T cells express the HLA-A*02, A*03, B*08, 
B*51, C*01 and C*07 class I alleles.
Production and purification of membrane HLA 
molecules
Cells lysate from two pellets of 12T cell lines were 
used for immunoaffinity purification of HLA molecules 
with their bound peptides, using the W6/32 mAb, bound 
to Amino-Link beads (Thermo Scientific, as in [20,21]). 
The HLA peptides were recovered from HLA molecules 
with 1% TFA followed by separation of the peptides from 
the proteins contaminants by binding the eluted fraction 
to disposable reversed-phase C18 columns (Harvard 
Apparatus). Elution of the peptides was done with 30% 
acetonitrile and 1% TFA. The eluted peptides were cleaned 
also by C18 stage tip as in [22] .
Identification of the HLA peptides
The HLA peptides were dried by vacuum 
centrifugation, re-solubilized with 0.1% Formic acid and 
resolved on capillary reversed phase chromatography on 
0.075x200 mm laser-pulled capillaries, self-packed with 
3µ Reprosil-Aqua C
18
 [23]. Electrospray tandem mass 
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spectrometry was performed with the Q-Exactive-Plus 
mass spectrometer (Thermo Scientific). The MS data was 
analyzed by MaxQuant [10] version 1.4.1.2, with 5% FDR 
and by Sequest using the Proteome Discoverer version 
1.4.1.14 (Thermo Scientific). Peptide identifications were 
based on the human section of the Uniprot database (http://
www.uniprot.org) from February 2014 combined with the 
wild type and mutant protein sequences.
Analysis of T cell responses 
TILs were isolated and expanded from fresh tumor 
digests as previously described [24] and EBV-transformed 
B-cell lines were established from PBLs of the patient 
(EBV was a gift from Prof. Ephraim Gazit). The reactivity 
of the TILs were evaluated by incubating patient derived 
EBV transformed B cells or T2 cells (with antigen-
processing defects that allow for the efficient loading of 
exogenous peptides [24]) with the candidate peptides at a 
concentration of 1 μM for 2 h at 37 °C. Following three 
washing steps, TILs were added at a ratio of 1:1 (1e5 
cells), and the amounts of soluble IFN-γ secreted from the 
TILs cultured overnight with peptide-pulsed target cells or 
tumor cells were measured by ELISA assay (Biolegend). 
Intracellular staining of IFN-γ
TILs were co-cultured with T2 cells pulsed with 
peptides or autologous melanoma cells for 6 hours. Then 
they were fixated using the Transcription Factor Buffer Set 
(BD Pharmingen), and stained anti IFN-γ, anti CD3 and 
anti CD8 (BD biosciences). Cells were analyzed using the 
FACSCalibur flow cytometer (BD biosciences). TILs were 
gated as positive for CD3 and CD8. 
cDNA sequencing
RNA was purified from cultured cells using 
RNAeasy mini kit (Qiagen) and cDNA was prepared 
using iScript reverse transcription supermix for RT-qPCR 
(Bio-Rad). The regions containing the mutation sites were 
amplified by PCR using KAPA HiFi HotStart ReadyMix 
PCR Kit (KAPAbiosystems). The PCR primer pairs used 
were: MED15 (5′- GGTGTCCCCTGAAGACCTTG) 
and (5′- CTGGGCCCAGGTGTTGAG); TPD52L2 
(5′- GCCGGCCAAGATATCAACCT) and (5′- 
GATCCGACAGGGGCTTGTC). PCR was performed 
using 100 ng cDNA and the following parameters: 1 cycle 
at 95°C for 3 min; 30 cycles at 98°C for 20 sec, annealing 
temperature of 65°C for 15 sec, 72°C for 60 sec; and 1 
cycle at 72°C for 1 min. PCR products were cleaned with 
QIAquick PCR Purification Kit (Qiagen) and sequenced 
using a 3730 DNA Analyzer (ABI). Sequencing primers 
were the same as the PCR primers.
RNA sequencing
RNA was extracted from 12T cells using RNeasy 
mini kit (Qiagen). 1 μg of total RNA was processed using 
the TruSeq RNA Sample Preparation Kit v2 protocol 
(Illumina). Libraries were evaluated by Qubit and 
TapeStation. Sequencing libraries were constructed with 
barcodes to allow multiplexing of few samples on one lane 
of Illumina HiSeq 2500 V4 instrument. About 60 million 
single-end 60-bp reads were sequenced. 
The TopHat (v2.0.10) was used to align the reads 
to the human genome (hg19), and counting reads on hg19 
refseq genes (downloaded from igenomes) was done with 
HTSeq-count (version 0.6.1p1).
RPKM values were calculated using Total exonic 
length for each gene, which was calculated using the 
bioconductor GenomicFeatures package.
Prediction of neo-antigens using NetMHCpan 2.8 
algorithm
The residues surrounding the amino acids resulting 
from nonsynonymous mutations were scanned to identify 
candidate 8-12 mer peptides that were predicted to 
bind with high affinity (strong binders, %Rank≤0.5 or 
IC50≤50) or low affinity (weak binders, 0.5≤%Rank≤2 
or 50≤IC50≤500) to the cells’ HLA-I alleles using the 
NetMHCPan 2.8 algorithm [4].
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